KYAN's mission is to
BRIDGE THE CANCER CARE GAP
by advancing revolutionary technologies
ADDRESSING THE CORE CHALLENGE OF CANCER TREATMENT
There is no silver bullet to treat cancer patients.
Cancer is not a single disease, but rather a group of diseases.
In total there are more than 100 different types of cancers that are dynamically expressed in each patient.
Identifying combinations therapies at different dosages is necessary when searching for the best cancer treatment. However, neither humans nor Big Data AI/ML can efficiently solve for large and complex set of predictions.
Our Technology
Our revolutionary phenotypic response technology is highly efficient in identifying safe and effective drug-dose combinations based on small inputs of data
EXPERIMENTAL BIOLOGY
Prospective experiments that identify the optimal phenotypic response surface across different biological models
SMALL DATA AI
SMALL DATA AI
Efficiently solve large and dynamic complex systems through a minimum number of tests
Efficiently solve large and dynamic complex systems through a minimum number of tests
Clinical Decision Support
We are building a Truly Personalized Medicine Solution that will help oncologists give cancer patients the tailored treatments they need
How it works
Liquid/Solid Biopsy
We separate the tumor cells while still fresh so that the cancer can be tested in its current state
Proprietary Drug Screening
Since any patient sample is limited in cells, we maximize the use with a proprietary design of experiments which gives us the right data to analyze
Computational Analysis
Our computational method maps each patient’s individual results for highly accurate drug response predictions
Report and Insights
Clinicians receive a clear and comprehensive report to better guide treatment for patients
Benefits of our approach
UNIQUE data and treatments for each patient's as their own cancer cells are used for drug response analysis
VAST number of regimens are evaluated to maximize finding effective treatment
ALL actionable treatments within a drug set can be ranked and compared, including against standard care
How we are different from standard care and other options
STANDARD THERAPY
SAME treatment for all patients and most will fail, requiring multiple lines of treatment
PRECISION MEDICINE
SMALL chance that patients have identifiable biomarkers matched with therapy (est. < 10%)
DRUG SENSITIVITY
LIMITED results when screening single drugs and preselected combinations
Biopharma Services
New target prioritization
Large search discovery for new targets + combinations
combination discovery
Explore combination discovery for lead targets
DOSE
OPTIMIZATION
Retrospective or prospective studies to support dose optimization within trials
Biomarker Identification
Find biomarker signatures based on phenotypic response curves
Revive
Failed Assets
Find new combination partners or companion Dx for assets that failed trials
Our Team
Hugo Saavedra
CEO
Lisa Chow
COO
Masturah Rashid
Head, R&D
Chih-Ming Ho
Scientific Co-founder
Edward Chow
Scientific Co-founder
Dean Ho
Scientific Co-founder
Advisors
Andreas Voss
Chief Medical Advisor
Phal Singh
Chief Financial Advisor
Rasha Kandil
Chief Regulatory Advisor
Wee Joo Chng
Director,National University Cancer Institute, Singapore
Carl Firth
Founder and CEO
ASLAN Pharmaceuticals
Katherine Wang
Project Director, Oncology Ascendis Pharma A/S
Aleidy Silva
Lead Field Applications Scientist Berkeley Lights
NEWS
September 2022
August 2022
June 2022
KYAN Therapeutics and Curie Oncology Announce Collaboration to Provide Personalized Cancer Test
May 2022
April 2022
November 2021
Data on Novel HDACi Targeting KRAS-mutated Cancers presented at the
AACR-KCA
Joint Conference on Precision Medicine in Solid Tumors
November 2021
November 2021
August 2021
Publications